SGLT2 inhibition in cardiology: What a cardiologist needs to knowAug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017
This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona
Video navigation menu
- Treatment with empagliflozin in the EMPA-REG OUTCOME trial showed a substantial reduction in CV death. 02:10
- Empagliflozin improves kidney function, leading to generalized decongestion, thereby benefitting the heart. 04:29
- The guidelines recommend using empagliflozin in patients with diabetes and CVD. 09:21
- Comparing the EMPA-REG OUTCOME and CANVAS study; results with empagliflozin and canagliflozin. 11:12
The educational objectives of this symposium were to:
- Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
- Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
- Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
- Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
- Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
Naveed Sattar, MD is Professor of Metabolic Medicine, OCDEM, University of Oxford. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease. He has authored or co-authored over 650 published papers, has received several national and international prizes for his research, and is in the top 1% of cited clinical academics in the world according to the Thomson Reuters 2016 Highly Cited Researcher list.
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
This symposum was supported by an unrestricted educational grants provided by Boehringer-Ingelheim/Lilly